According to this report the market is expected to reach US$ 76,282.63 million by 2027 from US$ 40,589.79 million in 2019; it is estimated to grow at a CAGR of 8.3% from 2020 to 2027. The report highlights trends prevailing in the global anti-viral therapies market and the drivers and restraints pertaining to the market growth.
Based on type, the global anti-viral therapies market is segmented into generic drugs and branded drugs. The generic drugs segment is estimated to register a higher CAGR in the market during 2020-2027. Rising demand for low-cost drugs, growing number of FDA-approved generic drugs, rising adoption in emerging nations, and patent expiry of various branded products are the factors boosting the market for the generic drugs segment.
The global anti-viral therapies market growth is mainly attributed to factors such as increasing R&D expenditure in pharmaceutical companies and rising government support for research activities and clinical trials. However, high drug development cost hinders the growth of the market.
AbbVie Inc.; Abbott; Astrazeneca; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma are among the leading companies operating in the anti-viral therapies market.
Reasons to Buy:
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the anti-viral therapies market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global anti-viral therapies market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Market Dynamics
Drivers
Increasing R&D Expenditures in Pharmaceutical Companies
Rising Government Support for Research Activities and Clinical Trials
Agnico Eagle Mines Limited ("Agnico Eagle" or the "Company") today reported financial and operating results for the first quarter of 2024.
"Building on a very strong close to 2023, we are reporting our second consecutive quarter of record...
OP Bancorp (the "Company") , the holding company of Open Bank (the "Bank"), today reported its financial results for the first quarter of 2024. Net income for the first quarter of 2024 was $5.23 million, or $0.34 per diluted common share, compared...
Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") .
Class Period: February 18, 2022 ?...
Hilton Grand Vacations Inc. announces today the completion of a $240 million securitization of legacy Bluegreen Vacations timeshare loans through Hilton Grand Vacations Trust 2024-1B ("the Trust"). Four classes of Notes were issued by the Trust,...
The Eastern Company today announced the declaration of its regular quarterly cash dividend of eleven cents ($0.11) per share, payable June 17, 2024, to common shareholders of record as of May 15, 2024. This dividend represents the Company's 335th...
The Hartford today announced financial results for the first quarter ended March 31, 2024.
"The Hartford's first quarter 2024 financial results were excellent with a trailing 12-month core earnings ROE of 16.6 percent," said The Hartford's...